期刊
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
卷 135, 期 12, 页码 1557-1560出版社
COLLEGE AMER PATHOLOGISTS
DOI: 10.5858/arpa.2010-0739-OA
关键词
-
资金
- NIH [EY017001]
- ONR MURI [N000141010278]
- NIH/NEI [1F32EY019819-01]
- Research Capacity Building Collaboration Wales
- British Society for Clinical Cytology
- National Association of Cytologists
Context.-Medical screening tasks are often difficult, visual searches with low target prevalence (low rates of disease). Under laboratory conditions, when targets are rare, nonexpert searchers show decreases in false-positive results and increases in false-negative results compared with results when targets are common. This prevalence effect is not due to vigilance failures or target unfamiliarity. Objective.-To determine whether prevalence effects could be a source of elevated false-negative errors in medical experts. Design.-We studied 2 groups of cytologists involved in cervical cancer screening (Boston, Massachusetts, and South Wales, UK). Cytologists evaluated photomicrographs of cells at low (2% or 5%) or higher (50%) rates of abnormality prevalence. Two versions of the experiment were performed. The Boston, Massachusetts, group made decisions of normal or abnormal findings using a 4-point rating scale. Additionally, the group from South Wales localized apparent abnormalities. Results.-In both groups, there is evidence for prevalence effects. False-negative errors were 17% (higher prevalence), rising to 30% (low prevalence) in the Boston, Massachusetts, group. The error rate was 27% (higher prevalence), rising to 42% (low prevalence) in the South Wales group. (Comparisons between the 2 groups are not meaningful because the stimulus sets were different.) Conclusions.-These results provide the first evidence, to our knowledge, that experts are not immune to the effects of prevalence even with stimuli from their domain of expertise. Prevalence is a factor to consider in screening for disease by human observers and has significant implications for cytology-based cervical cancer screening in the post-human papillomavirus vaccine era, when prevalence rates of high-grade lesions in the population are expected to decline. (Arch Pathol Lab Med. 2011; 135:1557-1560; doi:10.5858/arpa.2010-0739-OA)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据